At the news
? BULLISHIMPACT 5/10 6-K filed Jun 12, 2026 at 06:32 ET
GSK announced that momelotinib received Orphan Drug Designation (ODD) from the FDA and EMA for VEXAS syndrome, a rare life-threatening condition with no approved treatments. The designation supports the ongoing phase II/III ATLAS trial and potential future regulatory submissions, expanding momelotinib's development program beyond myelofibrosis.
- Momelotinib granted Orphan Drug Designation (ODD) by FDA and EMA for VEXAS syndrome.
- VEXAS syndrome has a 30-40% five-year mortality rate and no approved treatments.
- Phase II/III ATLAS trial evaluating momelotinib in VEXAS is underway; study design presented at EHA Congress June 11-14, 2026.
- Momelotinib is already approved for myelofibrosis in the US, EU, UK, and Japan.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access